Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT06892249
Recruiting Not applicable

Suitability of a High-energy, Low-protein Formula (Renalive® LP)

NCT06892249 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Fresenius Kabi Taiwan Ltd
Phase
Not applicable
Started
2025-06-04
Last updated
2026-10-01

Condition(s) studied

CKDLow Protein Dietary IntakeMalnutrition (Calorie)

Investigational drug(s) / intervention(s)

Renalive® LP,

Renalive® LP,: flavour

Study summary

Inclusion criteria (1) Diagnosed with chronic kidney disease stage 3b-5 (with history of eGFR\<45 mL/min/1.73 m2)

Exclusion criteria

(1) Has received dialysis or are expected to start dialysis within the next 3 months.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: (1) Diagnosed with chronic kidney disease stage 3b-5 (with history of eGFR\<45 mL/min/1.73 m2) Exclusion Criteria: (1) Has received dialysis or are expected to start dialysis within the next 3 months

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Kaosiung Chang Gung Memorial Hospital Kaohsiung City Taiwan Recruiting
Taipei TzuChi Hospital New Taipei City Taiwan Recruiting

More Fresenius Kabi Taiwan Ltd. trials in Taiwan

Evaluation of Safety and Efficacy of Supportan® Drink Recruiting

Other trials for the same condition

Study of Oral Uremic Toxin Absorbent and Probiotics to Retard the Progression of Chronic Kidney Disease Recruiting
lncRNAs as a Biomarker to Assess the Therapeutic Impact of Oral Absorbent ± Probiotics in CKD Patients With PAD Recruiting
Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity Recruiting
Oral Absorbent and Probiotics in CKD Patients With PAD on Gut Microbiota, IncRNA, Metabolome, and Vascular Function Recruiting
Evaluation of Safety and Efficacy of Supportan® Drink Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06892249 on ClinicalTrials.gov ↗ ← All trials in Taiwan